Ceramide Induces Cytochrome c Release from Isolated Mitochondria
IMPORTANCE OF MITOCHONDRIAL REDOX STATE*

Pedram GhafourifarDagger , Sabine D. Klein§, Olivier Schucht, Ursula Schenk, Martin Pruschy, Sonia Rocha, and Christoph Richterparallel

From the Laboratory of Biochemistry I, Swiss Federal Institute of Technology, Universitatsstrasse 16 and the  Department of Radiation Oncology, University Hospital of Zurich, CH-8092 Zurich, Switzerland

    ABSTRACT
Top
Abstract
Introduction
References

In the present study we show that N-acetylsphingosine (C2-ceramide), N-hexanoylsphingosine (C6-ceramide), and, to a much lesser extent, C2-dihydroceramide induce cytochrome c (cyto c) release from isolated rat liver mitochondria. Ceramide-induced cyto c release is prevented by preincubation of mitochondria with a low concentration (40 nM) of Bcl-2. The release takes place when cyto c is oxidized but not when it is reduced. Upon cyto c loss, mitochondrial oxygen consumption, mitochondrial transmembrane potential (Delta Psi ), and Ca2+ retention are diminished. Incubation with Bcl-2 prevents, and addition of cyto c reverses the alteration of these mitochondrial functions. In ATP-energized mitochondria, ceramides do not alter Delta Psi , neither when cyto c is oxidized nor when it is reduced, ruling out a nonspecific disturbance by ceramides of mitochondrial membrane integrity. Furthermore, ceramides decrease the reducibility of cyto c. We conclude that the apoptogenic properties of ceramides are in part mediated via their interaction with mitochondrial cyto c followed by its release and that the redox state of cyto c influences its detachment by ceramide from the inner mitochondrial membrane.

    INTRODUCTION
Top
Abstract
Introduction
References

Recently, the importance of ceramide in cell metabolism has been broadly investigated. It is now evident that ceramide is involved as a second messenger in what has become known as the sphingomyelin cycle (1), apoptosis, and differentiation in many cell types (2). The mechanisms by which ceramide mediates apoptosis have not yet been fully addressed, however, it is known that mitochondria are targets of ceramide. Thus, direct inhibition of complex III of the mitochondrial respiratory chain by ceramide (3), ceramide-induced generation of reactive oxygen species in intact mitochondria (4) and in cells (5, 6), and ceramide-induced cell death via disruption of mitochondrial functions (7) are lines of evidence of the strong influence of ceramide on mitochondria.

Cytochrome c (cyto c)1 plays a dual role in cell homeostasis. As a part of the respiratory chain, it is needed for cell life, and as one of the triggers of apoptosis, it is needed for cell death. It is now well accepted that many apoptogenic factors induce cell death via mitochondrial cyto c release (8). The released cytochrome switches on the death machinery, for example, by activation of caspases (9, 10). The anti-apoptoic protein, Bcl-2, was shown to prevent apoptosis both upstream (8) and downstream (11) of cyto c release.

In the present study we show that 1) C2-ceramide (N-acetylsphingosine), C6-ceramide (N-hexanoylsphingosine), and, to a much lesser extent, DHC (C2-dihydroceramide) release cyto c from isolated mitochondria, 2) ceramide-induced cyto c release occurs when cyto c is oxidized but not when it is reduced, 3) this release is prevented by Bcl-2, 4) cyto c release causes a decrease in mitochondrial oxygen consumption, transmembrane potential (Delta Psi ), and Ca2+ retention, all of which are prevented by preincubation of mitochondria with Bcl-2 and reversed by addition of cyto c, and 5) ceramide interacts with cyto c and changes its reducibility.

    EXPERIMENTAL PROCEDURES

C2- and C6-ceramide were obtained from Alexis Biochemicals (Läufelfingen, Switzerland), DHC from Calbiochem (Luzern, Switzerland), horse heart cytochrome c from Sigma, mouse monoclonal cyto c antibody from RDI (Flanders, NJ), anti-mouse Ig and horseradish peroxidase from Amersham and His6-human Bcl-2 from Novartis (Basel, Switzerland). Ceramide stock solutions were prepared at a 500 times concentration in ethanol (containing 1% Me2SO) and kept at -20 °C. The vehicle always served as control.

Mitochondrial Preparation-- Isolation of rat liver mitochondria was performed by differential centrifugation as described (12). The protein content of mitochondria and the mitochondrial supernatants were determined by the Biuret method with bovine serum albumin as standard.

Detection of Cytochrome c Release-- Freshly isolated mitochondria (10 mg protein/ml) were incubated at room temperature in 0.1 M HEPES buffer, pH 7.0, containing aprotinin, pepstatin A, and leupeptin (1.5 µg/ml each). To investigate the effect of ceramide when cyto c is oxidized, mitochondrial respiratory chain complex III was blocked by 50 nM antimycin A (AA), and after 1 min, ceramide (20 µM) or the vehicle was added. Mitochondria were incubated for 2 min and then energized with 1 mM ascorbate (Asc) plus 0.4 mM tetramethyl-1,4-phenylenediamine (TMPD) (Asc/TMPD). The effect of ceramide on mitochondria when cyto c is reduced was studied by addition of ceramide 1 min after Asc/TMPD. Bcl-2 (40 nM) was added 5 min before AA. After 10 min of incubation at room temperature, mitochondria were spun at 12,000 × g for 10 min at 4 °C, and the resulting supernatant was spun at 100,000 × g for 15 min at 4 °C. The supernatant of the second centrifugation was used for the detection of cyto c either spectrophotometrically or by gel electrophoresis. Spectrophotometric measurements were done in a Varian Cray spectrophotometer. As the blank sample, 10 mg of mitochondrial protein was diluted in 1 ml of the buffer, mixed gently, and spun immediately in 2 steps as mentioned above, and the supernatant was considered as the blank. The absorption of the supernatants of mitochondria incubated with ceramide or the vehicle was then recorded before and after reduction with sodium dithionite. The concentration of cyto c was calculated using an extinction coefficient of 19.0 mM-1 cm-1 for reduced cyto c at 550-540 nm (13) and is expressed as the percentage of the control. For gel analysis, 20 µl of the supernatant of mitochondria incubated with ceramide or the vehicle was separated by 15% SDS-PAGE and stained with Coomassie Blue. For Western blotting, 20 µg of protein of supernatants were separated by 15% SDS-PAGE, blotted onto a nitrocellulose membrane, probed by a monoclonal mouse anti-cyto c antibody, and developed by enhanced chemiluminescence.

For studying the possible influence of Delta Psi on mitochondrial cyto c release, Delta Psi was fully abrogated by incubation of mitochondria with 5 µM rotenone, 50 nM AA, and 1 µM carbonyl cyanide m-chlorophenylhydrazone. The absence of Delta Psi was verified as explained below. After 10 min, mitochondria were spun as described above, and the supernatant was tested for the presence of cyto c by Western blotting.

Analysis of Mitochondrial Functions-- For studying mitochondrial functions, 1 mg of mitochondrial protein/ml was incubated in 0.1 M HEPES buffer, pH 7.0, with the following compounds present where appropriate: 10-20 µM ceramide, 50 nM AA to block complex III, Asc/TMPD to reduce cyto c, 1 mM KCN to block complex IV, 1 mM ATP as the substrate of ATPase, 1 µM carbonyl cyanide m-chlorophenylhydrazone to uncouple mitochondria, and 1.7 µg/ml oligomycin to block ATPase. Ceramide was added when cyto c was oxidized, i.e. after AA, or when it was reduced, i.e., after Asc/TMPD. Bcl-2 was added 5 min prior to the above mentioned compounds.

Oxygen consumption was measured at room temperature with a Clark-type oxygen electrode (Yellow Spring Instruments, Yellow Spring, OH) under continuous stirring. Mitochondrial transmembrane potential was measured in an Aminco DW-2A spectrophotometer at 511-533 nm in the presence of 10 µM safranin as described (14). Mitochondrial Ca2+ uptake and release was measured in 0.1 M HEPES buffer, pH 7.0, containing 10 µM CaCl2 (10 nmol of Ca2+/mg of mitochondrial protein) at 685-675 nm in the presence of 50 µM Arsenazo III as described (15).

Assessment of Cytochrome c Reduction-- The optical density of a 10 µM oxidized horse heart cyto c solution in the presence of 10 µM ceramide or the vehicle was recorded between 380 and 600 nm at 1-nm intervals with a Varian Cray spectrophotometer. Oxidized cyto c was then reduced stepwise by the repeated addition of 2 µM ascorbate (taken from a 2 mM freshly prepared stock solution) to the cuvette. After each reduction step, the optical density was again recorded. The recorded optical density of the oxidized cyto c in each wavelength was subtracted from the corresponding one of the reduced cyto c and plotted against the wavelengths.

    RESULTS

Ceramide-induced mitochondrial cyto c release was determined by SDS-PAGE (Fig. 1A), by Western blotting (Fig. 1B), and spectrophotometrically (Fig. 1C). In these experiments, ceramide was added when cyto c was mainly oxidized, i.e. after blocking the complex III. Addition of ceramide to mitochondria when cyto c was mainly reduced, i.e., in the presence of Asc/TMPD, did not increase the released cyto c, compared to the control (Fig. 1D). Preincubation of mitochondria with 40 nM Bcl-2 (4 pmol of Bcl-2/mg of mitochondrial protein) fully prevented the release of cyto c induced by ceramide (see Fig. 1B). When equal volumes (20 µl) of the supernatants of mitochondria incubated with ceramides were separated by SDS-PAGE, an increase in the total protein amount released into the supernatant was detected (Fig. 1A). When equal amounts (20 µg) of the released proteins were analyzed by Western blot, a specific increase in the cyto c was found (Fig. 1B).


View larger version (56K):
[in this window]
[in a new window]
 
Fig. 1.   Ceramide-induced cyto c release from rat liver mitochondria. Release was assayed by Coomassie Blue staining (A), Western blotting (B), and spectrophotometry (C). In these experiments, ceramide was added when cyto c was oxidized. In D (Coomassie Blue staining), ceramide was added when cyto c was reduced. Mitochondria were treated with vehicle (Cont), C2-ceramide (C2), C6-ceramide (C6), or DHC (for details, see under "Experimental Procedures"). The left lane of A and D shows 5 µg of pure cyto c (arrowhead).

To investigate the consequences of cyto c release on mitochondrial functions, we measured mitochondrial oxygen consumption, Delta Psi , and Ca2+ homeostasis. Fig. 2A shows that addition of ceramide to mitochondria when cyto c was oxidized decreased the oxygen consumption supported by Asc/TMPD. Conversely, ceramide added to mitochondria when cyto c was reduced did not change the oxygen consumption (Fig. 2B). The decreased oxygen consumption caused by ceramide was prevented by preincubation of mitochondria with 40 nM Bcl-2 (Fig. 2C) and was reversed by the addition of 200 nM exogenous cyto c (200 pmol of cyto c/mg of mitochondrial protein) (Fig. 2D).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 2.   . Mitochondrial oxygen consumption in the presence of ceramide. 10 µM ceramide was added when cyto c was oxidized (A) or reduced (B). C, as for A except that mitochondria were preincubated for 5 min with 40 nM Bcl-2. D, as A except that 200 nM cyto c was added at the point marked by the asterisk. Mitochondria were treated with vehicle (Cont), C2-ceramide (C2), C6-ceramide (C6), or DHC (for details, see under "Experimental Procedures"). down-triangle, addition of AA; black-down-triangle , addition of Asc/TMPD.

A decrease in Delta Psi is considered important when cells commit suicide (16). Fig. 3A shows that addition of ceramide to mitochondria when cyto c was oxidized caused a decrease in Delta Psi . This figure also shows that addition of 200 nM exogenous cyto c resulted in a full gain of Delta Psi . Incubation of mitochondria with 40 nM Bcl-2 prevented the loss of Delta Psi caused by ceramide (not shown). Fig. 3B shows that ceramide did not alter Delta Psi when cyto c was mainly reduced. When Delta Psi was built up as a consequence of ATP hydrolysis instead of respiration, ceramide did not change Delta Psi , neither when cyto c was oxidized nor when it was reduced (not shown).


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 3.   . Transmembrane potential of mitochondria exposed to ceramide. Ceramide was added (arrows) when cyto c was oxidized (A) or reduced (B). Addition of 200 nM cyto c is indicated by asterisks (A). Mitochondria were treated with vehicle (Cont), C2-ceramide (C2), C6-ceramide (C6), or DHC (for details, see under "Experimental Procedures").

Mitochondria are important calcium buffers in eukaryotic cells, and mitochondrial calcium release is involved in apoptosis (17). Fig. 4 shows that C6-ceramide, added to mitochondria when cyto c was mainly oxidized, caused a decrease in Ca2+ retention by mitochondria, in a Bcl-2 sensitive manner. The same results were obtained with C2-ceramide and, to a minor extent, with DHC (not shown). Addition of ceramide to mitochondria when cyto c was reduced did not change the mitochondrial Ca2+ homeostasis (not shown).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 4.   . Mitochondrial Ca2+ homeostasis in the presence of ceramide. Mitochondria were incubated in 0.1 M HEPES buffer containing 10 nM Ca2+/mg mitochondrial protein. triangle , addition of AA; black-down-triangle , addition of Asc/TMPD. C6-ceramide (C6) or vehicle (Cont) was added at the dashed arrow. When present, Bcl-2 was added 5 min before AA (for details, see under "Experimental Procedures").

Reduction of cyto c can be followed photometrically. Fig. 5 shows that in the presence of C2-ceramide, the reduction of cyto c by Asc was hampered, as evidenced by the smaller increase in the optical densities of the gamma - and alpha -regions. Again, C2-ceramide was most effective, followed by C6-ceramide and DHC (not shown).


View larger version (49K):
[in this window]
[in a new window]
 
Fig. 5.   Reduction of cyto c in the presence of ceramide. 10 µM oxidized cyto c was reduced by the stepwise addition of Asc in the presence of vehicle (Cont) or 10 µM C2-ceramide (C2). A typical experiment out of five is shown (for details, see under "Experimental Procedures").


    DISCUSSION

The present study shows that ceramide induces cyto c release from isolated mitochondria, an event strongly influenced by the redox state of cyto c, and that incubation of mitochondria with Bcl-2 prevents the cyto c release. Release of cyto c decreases mitochondrial oxygen consumption, Delta Psi , and the Ca2+ buffering capacity of mitochondria, all of which are reversed by addition of exogenous cyto c. For all parameters measured, the observed rank order of potency is C2 > C6 > DHC. This study also provides evidence for a possible direct interaction of ceramide and cyto c.

There is growing evidence that mitochondria are involved in apoptosis (16). The release of cyto c from mitochondria triggers apoptosis (18), and Delta Psi decreases during apoptosis (16, 19-21). Accordingly, prevention of cyto c release (22) as well as stabilization of Delta Psi (23) prevent apoptosis. Furthermore, mitochondria carry the pro- and antiapoptotic proteins, cyto c and Bcl-2. The presence of procaspase-3 in mitochondria was also shown recently (24).

Several mediators, pathways, and factors are involved in apoptosis (25, 26). Among them, ceramide has been shown to directly target mitochondria. Zhang et al. (27) showed that in Molt-4 leukemic cells, 6 h of incubation with C6-ceramide increased the cytosolic concentration of cyto c, which was preventable by overexpression of Bcl-2. In a study by Amarante-Mendes et al. (28) 6 h of incubation with C2-ceramide caused the cytosolic accumulation of cyto c in control but not in Bcr-Abl-overexpressing HL-60 cells. In the present study, we show that ceramide directly causes the release of cyto c from isolated mitochondria and accordingly hypothesize that cyto c is the prime mitochondrial target of ceramide. The fact that incubation of mitochondria with a low concentration of Bcl-2, used in this study, prevents ceramide-induced cyto c release and its consequences suggests a specific function of the oncoprotein in ceramide-mediated apoptotic signals.

To investigate a possible direct interaction of ceramide with cyto c, we primed Sepharose columns with the biologically active D-C2-ceramide or biologically inactive L-C2-ceramide.2 We observed that D-C2-ceramide but not L-C2-ceramide columns selectively retained cyto c and that the retained protein could be eluted with D-C2-ceramide. We also observed that reduced cyto c had a much lower affinity to D-C2-ceramide column, compared to the oxidized cyto c. Because of that observation together with the fact that ceramide affects the reducibility of cyto c (Fig. 5), we hypothesize that ceramide may directly interact with cyto c, with a higher affinity for the oxidized protein, and that this interaction changes the physicochemical properties of cyto c, leading to its rejection from mitochondria. The fact that cyto c has multiple lipid binding sites and that the lipid-bound cyto c shows a lower affinity for attachment to the artificial membranes (29) strengthens this hypothesis.

Under our experimental conditions, prevention of mitochondrial cyto c reduction is paralleled by the disappearance of Delta Psi . To distinguish which of these two is decisive for ceramide-induced cyto c release, we investigated by Western blot analysis whether cyto c is released because of Delta Psi collapse. We found that the absence of Delta Psi , achieved by blocking respiration and uncoupling of mitochondria, does not result in cyto c release, indicating that binding of cyto c to the outer side of the inner mitochondrial membrane does not require Delta Psi . These results also indicate that the release of cyto c by ceramide is not a consequence of a nonspecific solubilization of mitochondrial membranes due to the lipophilicity of ceramide, but rather is a specific event.

The release of other mitochondrial proteins apart from cyto c is also increased upon treatment with ceramide (Fig. 1A). We argue that this apparently nonspecific protein release by ceramide is due to a general weakening of mitochondria upon cyto c release. Fig. 1D supports this argument by showing that when ceramide does not cause cyto c loss, other mitochondrial proteins are also not released. This notion, together with the fact that addition of exogenous cyto c reverses all the altered mitochondrial functions, leads us to conclude that mitochondrial cyto c is a prime target for ceramide. This conclusion does not rule out other possibilities, for example, the modification of Bcl-2 by ceramide.

In contrast to the finding that binding of cyto c to the inner mitochondrial membrane is not a function of Delta Psi , the formation and the maintenance of Delta Psi is dependent on the presence of a functional cyto c (cf. Fig. 3A). Disruption of Delta Psi was shown to be involved in ceramide-induced apoptosis (30). According to our study, cyto c has a critical role in Delta Psi formation, in that stabilization of cyto c stabilizes Delta Psi . Bcl-2 is located at the outer mitochondrial membrane (31) and has been shown to stabilize Delta Psi (23). It is known that Bcl-xL, another oncoprotein with mitochondrial location, binds cyto c (32). Based on the present results and the close proximity of Bcl-2 to mitochondrial cyto c, it may be speculated that Bcl-2 stabilizes Delta Psi by preventing cyto c loss.

Nonspecific solute transport across the inner mitochondrial membrane, operated via a Bcl-2-sensitive megachannel (the "permeability transition pore") is considered to be the reason for the collapse of Delta Psi and many other features of apoptosis (reviewed in Ref. 33). It was also reported that operation of such a pore causes cyto c release, and thus it was concluded that cyto c release occurs downstream to pore formation and Delta Psi collapse (34). Because addition of cyto c reverses the ceramide-induced decrease in mitochondrial oxygen consumption, Delta Psi , and Ca2+-maintaining capacity (see Figs. 2-4), we argue that ceramide-induced apoptosis is not mediated via opening a nonspecific megachannel or pore. The fact that ceramide does not affect Delta Psi when it is supported by ATP gives further support to this argument.

It was reported by Gudz et al. (3) that ceramide decreases the activity of complex III of the mitochondrial respiratory chain, as deduced from the measurement of mitochondrial oxygen consumption supported by Asc/TMPD. Cyto c shuttles electrons between complex III and IV, and oxygen is consumed at the level of complex IV. Figs. 2D and 3A show that the addition of cyto c to mitochondria recovered the decreased respiration and the reduced Delta Psi . Therefore, we conclude that parts of the ceramide-induced reduction of complex III activity is due to cyto c loss.

Garcia-Ruiz et al. (4) showed that ceramide induces superoxide radical formation in isolated rat liver mitochondria. From the elegant recent study by Cai and Jones (35), it is evident that superoxide formation by mitochondria is a consequence, and not the cause, of cyto c loss. Release of cyto c from mitochondria produces a gap in the hierarchically arranged mitochondrial respiratory complexes III and IV, and therefore a site for electron leakage. Present finding explains the ceramide-induced superoxide formation, reported by Garcia-Ruiz et al. (4), and supports the hypothesis that cyto c is the prime mitochondrial site of action of ceramide.

We reported (23) that TNF-alpha added to cells induces a drop in Delta Psi that is accompanied by increased reactive oxygen species formation in mitochondria and that both events are prevented in Bcl-2-overexpressing cells. It is known that de novo ceramide synthesis is part of the transmembrane signaling transduction mechanism of TNF-alpha receptor (36-40). It was also reported that stimulation of TNF-alpha receptors causes apoptotic cell death by releasing mitochondrial cyto c (41). The present study makes the link: after de novo ceramide synthesis upon TNF-alpha receptor stimulation, mitochondrial cyto c is released, Delta Psi is decreased, and reactive oxygen species formation is favored. Accordingly, overexpression of Bcl-2 prevents the apoptogenic properties of TNF-alpha (37) by prevention of ceramide-induced cyto c release.

It was reported by Hampton et al. (42) that cyto c does not necessarily need to be reduced to activate caspases. The investigators acknowledged, however, that they were unable to keep cyto c oxidized in the presence of cytosolic extracts. In the present study, we show that oxidized cyto c is released by ceramide (Fig. 1, A-C) and that ceramide decreases the reducibility of oxidized cyto c (Fig. 5). Regarding the fact that both ceramide and cyto c are strong mediators of caspase-induced apoptosis (43), the possible interaction of ceramide and cyto c may thus amplify the progression of the apoptotic cascade.

    ACKNOWLEDGEMENTS

We thank Dr. Wolfgang Blodig for very useful discussions, Dr. Theresa Visarius for critically reading the manuscript, Novartis Pharma AG for providing Bcl-2, and Dr. Kaspar H. Winterhalter for his interest and support. D- and L-ceramide Sepharose affinity chromatography columns were a generous gift of Dr. Joseph Brunner, Federal Institute of Technology (Zurich, Switzerland).

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Parts of this work were presented in the Biochemical Society meeting, Sheffield, United Kingdom, July 1998.

Dagger Financially supported by Swiss National Research Foundation Grant 31-45821.95.

§ Financially supported by Leica and Avina Foundation (Switzerland).

parallel To whom correspondence should be addressed. Tel.: 41-1-632-31-36; Fax: 41-1-632-11-21; E-mail: richter{at}bc.biol.ethz.ch.

2 P. Ghafourifar, C. Richter, and J. Brunner, unpublished observation.

    ABBREVIATIONS

The abbreviations used are: cyto c, cytochrome c; AA, antimycin A; Asc, ascorbate; TMPD, tetramethyl-1,4-phenylenediamine; C2-ceramide, N-acetylsphingosine; C6-ceramide, N-hexanoylsphingosine; DHC, C2-dihydroceramide; Delta Psi , mitochondrial transmembrane potential; PAGE, polyacrylamide gel electrophoresis.

    REFERENCES
Top
Abstract
Introduction
References
  1. Hannun, Y. A. (1994) J. Biol. Chem. 269, 3125-3128[Free Full Text]
  2. Bose, R., Verheij, M., Haimovitz-Friedman, A., Scotto, K., Fuks, Z., and Kolesnick, R. (1995) Cell 82, 405-414[Medline] [Order article via Infotrieve]
  3. Gudz, T. I., Tserng, K. Y., and Hoppel, C. L. (1997) J. Biol. Chem. 272, 24154-24158[Abstract/Free Full Text]
  4. Garcia-Ruiz, C., Colell, A., Mari, M., Morales, A., and Fernandez-Checa, J. (1997) J. Biol. Chem. 272, 11369-11377[Abstract/Free Full Text]
  5. Quillet-Mary, A., Jaffrézou, J.-P., Mansat, V., Bordier, C., Naval, J., and Laurent, G. (1997) J. Biol. Chem. 272, 21388-21395[Abstract/Free Full Text]
  6. FranceLanord, V., Brugg, B., Michel, P. P., Agid, Y., and Ruberg, M. (1997) J. Neurochem. 69, 1612-1621[Medline] [Order article via Infotrieve]
  7. Arora, A. S., Jones, B. J., Patel, T. C., Bronk, S. F., and Gores, G. J. (1997) Hepatology 25, 958-963[Medline] [Order article via Infotrieve]
  8. Kluck, R. M., Bossy Wetzel, E., Green, D. R., and Newmeyer, D. D. (1997) Science 5303, 1132-1136
  9. Liu, X., Kim, C. N., Yang, J., Jemmerson, R., and Wang, X. (1996) Cell 86, 147-157[Medline] [Order article via Infotrieve]
  10. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., and Wang, X. (1997) Cell 91, 479-489[Medline] [Order article via Infotrieve]
  11. Zhivotovsky, B., Orrenius, S., Brustugun, O. T., and Doskeland, S. O. (1998) Nature 391, 469-450
  12. Lötscher, H. R., Winterhalter, K. H., Carafoli, E., and Richter, C. (1980) J. Biol. Chem. 255, 9325-9330[Abstract/Free Full Text]
  13. Dutton, P. L., Petty, K. M., Bonner, H. S., and Morse, S. D. (1975) Biochim. Biophys. Acta 387, 536-556[Medline] [Order article via Infotrieve]
  14. Schweizer, M., and Richter, C. (1996) Biochemistry 35, 4524-4528[CrossRef][Medline] [Order article via Infotrieve]
  15. Frei, B., Winterhalter, K. H., and Richter, C. (1985) J. Biol. Chem. 260, 7394-7401[Abstract/Free Full Text]
  16. Mignotte, B., and Vayssiere, J. L. (1998) Eur. J. Biochem. 252, 1-15[Abstract]
  17. Kruman, I., Guo, Q., and Mattson, M. P. (1998) J. Neurosci. Res. 51, 293-308[CrossRef][Medline] [Order article via Infotrieve]
  18. Rossé, T., Olivier, R., Monney, L., Rager, M., Conus, S., Fellay, I., Jansen, B., and Borner, C. (1998) Nature 391, 496-499[CrossRef][Medline] [Order article via Infotrieve]
  19. Shidoji, Y., Nakamura, N., Moriwaki, H., and Muto, Y. (1997) Biochem. Biophys. Res. Commun. 230, 58-63[CrossRef][Medline] [Order article via Infotrieve]
  20. Inai, Y., Yabuki, M., Kanno, T., Akiyama, J., Yasuda, T., and Utsumi, K. (1997) Cell Struct. Func. 22, 555-563[Medline] [Order article via Infotrieve]
  21. Wadia, J. S., ChalmersRedman, R. M. E., Ju, W. J. H., Carlile, G. W., Phillips, J. L., Fraser, A. D., and Tatton, W. G. (1998) J. Neurosci. 18, 932-947[Abstract/Free Full Text]
  22. Macho, A., Hirsch, T., Marzo, I., Marchetti, P., Dallaporta, B., Susin, S. A., Zamzami, N., and Kroemer, G. (1998) J. Immunol. 158, 4612-4619[Abstract]
  23. Hennet, T., Bertoni, G., Richter, C., and Peterhans, E. (1993) Cancer Res. 53, 1456-1460[Abstract]
  24. Mancine, M., Nicholson, D. W., Roy, S., Thornberry, N. A., Peterson, E. P., Casciola-Rosen, L. A., and Rosen, A. (1998) J. Cell Biol. 140, 1485-1495[Abstract/Free Full Text]
  25. Thompson, C. B. (1995) Science 267, 1456-1462[Medline] [Order article via Infotrieve]
  26. Hermann, S. (1995) Science 267, 1445-1449[Medline] [Order article via Infotrieve]
  27. Zhang, P., Liu, B., Kang, S. W., Seo, M. S., Rhee, S. G., and Obeid, L. M. (1997) J. Biol. Chem. 272, 30615-30618[Abstract/Free Full Text]
  28. Amarante-Mendes, G. P., Naekyung Kim, C., Liu, L., Huang, Y., Perkins, C. L., Green, D. R., and Bhalla, K. (1998) Blood 91, 1700-1705[Abstract/Free Full Text]
  29. Subramanian, M., Jutila, A., and Kinnunen, P. K. J. (1998) Biochemistry 37, 1394-1402[CrossRef][Medline] [Order article via Infotrieve]
  30. De-Maria, R., Lenti, L., Malisan, F., d'Agostino, F., Tomassini, B., Zeuner, A., Rippo, M. R., and Testi, R. (1997) Science 277, 1652-1655[Abstract/Free Full Text]
  31. Lithgow, T., van Driel, R., Bertram, J. F., and Strasser, A. (1994) Cell Growth Differ. 4, 411-417[Abstract]
  32. Kharbanda, S., Pandey, P., Schofield, L., Israels, S., Roncinske, R., Yoshida, K., Bharti, A., Yuan, Z., Saxena, S., Weichselbaum, R., Nalin, C., and Kufe, D. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 6939-6942[Abstract/Free Full Text]
  33. Hirsch, T., Marzo, I., and Kroemer, G. (1997) Biosci. Rep. 17, 67-76[Medline] [Order article via Infotrieve]
  34. Yang, J. C., and Cortopassi, G. A. (1998) Free Radical Biol. Med. 24, 624-631[CrossRef][Medline] [Order article via Infotrieve]
  35. Cai, J., and Jones, D. P. (1998) J. Biol. Chem. 273, 11401-11404[Abstract/Free Full Text]
  36. Kuroki, J., Hirokawa, M., Kitabayashi, A., Lee, M., Horiuchi, T., Kawabata, Y., and Miura, A. B. (1996) Leukemia 10, 1950-1958[Medline] [Order article via Infotrieve]
  37. Dbaibo, G. S., Perry, D. K., Gamard, C. J., Platt, R., Poirier, G. G., Obeid, L. M., and Hannun, Y. A. (1997) J. Exp. Med. 185, 481-490[Abstract/Free Full Text]
  38. Higuchi, M., Singh, S., Jaffrezou, J. P., and Aggarwal, B. B. (1996) J. Immunol. 157, 297-304[Abstract]
  39. Kitajima, I., Soejima, Y., Takasaki, I., Beppu, H., Tokioka, T., and Maruyama, I. (1996) Bone 19, 263-270[CrossRef][Medline] [Order article via Infotrieve]
  40. Bezombes, C., Maestre, N., Laurent, G., Levade, T., Bettaieb, A., and Jaffrezou, J. P. (1998) FASEB J. 12, 101-109[Abstract/Free Full Text]
  41. Tang, D. G., Li, L., Zhu, Z. Y., and Joshi, B. (1998) Biochem. Biophys. Res. Commun. 242, 380-384[CrossRef][Medline] [Order article via Infotrieve]
  42. Hampton, M. B., Zhivotovsky, B., Slater, A. F. G., Burgess, D. H., and Orrenius, S. (1998) Biochem. J. 329, 95-99[Medline] [Order article via Infotrieve]
  43. Tepper, A. D., Boesen-de-Cock, J. G. R., de Vries, E., Borst, J., and van Blitterswijk, W. J. (1997) J. Biol. Chem. 272, 24308-24312[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.